← Drug-vs-drug verdicts

Ozempic vs Mounjaro: The Diabetes Pair, Compared Head-to-Head

Ozempic (semaglutide, Novo Nordisk) vs Mounjaro (tirzepatide, Eli Lilly)

Last verified May 2026

By Ruth Calder · Enforcement Editor
Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed

The verdict

Neither drug carries a weight-loss label — both treat type 2 diabetes, and both get prescribed off-label for weight constantly. SURPASS-2 compared them directly: −11.2 kg on Mounjaro 15 mg against −5.7 kg on Ozempic 1 mg over 40 weeks, with a larger A1C drop too. Ozempic carries the completed cardiovascular result — MACE −26% in SUSTAIN-6. Retail pricing is close, near $1,000 either way, and neither has a real manufacturer cash-pay tier for weight loss.

Side-by-side comparison

FieldOzempicMounjaro
Mean weight loss (TBWL, head-to-head)-5.7 kg / 40 wks (Ozempic 1mg)-11.2 kg / 40 wks (Mounjaro 15mg)
A1C reduction (SURPASS-2)-1.86% (Ozempic 1mg)-2.30% (Mounjaro 15mg)
MechanismGLP-1 receptor agonistDual GIP / GLP-1 agonist
FDA-approved indicationType 2 diabetes; CV risk reduction in T2D + CVDType 2 diabetes (weight management requires Zepbound)
Cardiovascular outcomeMACE -26% (SUSTAIN-6, 2016)SURPASS-CVOT pending 2027
DosingOnce-weekly subq 0.25-2.0 mg (4-step titration)Once-weekly subq 2.5-15 mg (6-step titration)
Most common adverse eventNausea (~20% at 1mg; SUSTAIN-7)Nausea (~22% at 15mg; SURPASS-2)
Cash price (US, ~2026)~$998/mo retail (no manufacturer cash-pay program)~$1,069/mo WAC (Lilly savings card for commercial)

What each one costs in the compounded market

Standing monthly cash prices from the 556 sellers on this register. These are compounded preparations, not the approved products compared above.

Ozempicsemaglutide

from $79 /mo

283 sellers publish a standing price; the median is $174 a month.

Mounjarotirzepatide

from $99 /mo

253 sellers publish a standing price; the median is $240 a month.

⚠ A compounded preparation is not the approved product. No agency has reviewed that specific preparation for safety, effectiveness or manufacturing quality, and the legal ground under compounding these molecules narrowed when the shortages closed. The price gap is real, and so is the difference in oversight. Every seller, with its price record.

Frequently asked questions

Which works better for weight loss, Ozempic or Mounjaro?

On the trial evidence, Mounjaro: Ozempic at -5.7 kg / 40 wks (Ozempic 1mg) against Mounjaro at -11.2 kg / 40 wks (Mounjaro 15mg), measured head-to-head. That is the strongest form of this evidence, because both arms run under one protocol rather than being two separate studies set side by side.

Are Ozempic and Mounjaro the same drug?

No. Ozempic is semaglutide and Mounjaro is tirzepatide — different molecules, and they work differently: GLP-1 receptor agonist against Dual GIP / GLP-1 agonist. Results with one do not predict results with the other.

Is Ozempic or Mounjaro cheaper?

On the manufacturers' own cash pricing: Ozempic at ~$998/mo retail (no manufacturer cash-pay program), Mounjaro at ~$1,069/mo WAC (Lilly savings card for commercial). ⚠ That is the list-price comparison, and it is not what most people pay. What you actually pay depends on whether your plan covers it, which formulary tier it sits in, and whether you have met your deductible — and for many people the honest comparison is between an insured copay and a cash-pay compounded alternative rather than between these two figures.

Does either one have better cardiovascular evidence?

Ozempic does. Ozempic: MACE -26% (SUSTAIN-6, 2016). Mounjaro: SURPASS-CVOT pending 2027. This matters more than it first appears — a drug with a completed outcomes trial has evidence about events that matter, not only about weight, and that is often what decides coverage.

Which has worse side effects, Ozempic or Mounjaro?

The most common adverse event reported was Nausea (~20% at 1mg; SUSTAIN-7) for Ozempic and Nausea (~22% at 15mg; SURPASS-2) for Mounjaro. ⚠ Rates come from separate trial populations and are not a like-for-like comparison. In practice how fast the dose is escalated affects tolerability at least as much as which drug it is, which is one reason a slower titration is worth asking for.

How is each one taken?

Ozempic: Once-weekly subq 0.25-2.0 mg (4-step titration). Mounjaro: Once-weekly subq 2.5-15 mg (6-step titration). Worth weighing honestly against your own habits — the best drug for you is partly the one you will still be taking in eight months, and a dosing routine that does not fit a life gets abandoned.

What does a compounded version of each actually cost?

Across the 556 sellers in this register, the cheapest standing monthly cash prices we hold are semaglutide from $79 a month and tirzepatide from $99 a month. ⛔ A compounded preparation is not the approved product: no agency has reviewed that specific preparation for safety, effectiveness or manufacturing quality, and the legal ground under compounding these molecules narrowed once the shortages closed. The price gap is real and so is the difference in oversight.

Can I switch from Ozempic to Mounjaro?

Yes, with a prescriber. Expect to re-titrate from the bottom of the new drug's ladder rather than starting where you left off: these are different molecules and tolerance to one does not transfer to the other. Both the old drug's washout and the new drug's schedule apply.

Which one should I ask for?

That is a prescriber's call, and anyone answering it from a table is guessing. What a page like this can do is tell you what the trials measured, what the manufacturers charge, and where the evidence is still missing, so the conversation starts from the record rather than from an advertisement.

References

  1. 1.Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med. 2021. PMID: 34170647.
  2. 2.Pratley RE, Aroda VR, Lingvay I, Lüdemann J, Andreassen C, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. 2018. PMID: 29397376.
  3. 3.Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). N Engl J Med. 2016. PMID: 27633186.
  4. 4.Novo Nordisk Pharmaceutical Industries, LP. OZEMPIC (semaglutide) injection prescribing information. DailyMed (FDA label). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79
  5. 5.Eli Lilly and Company. MOUNJARO (tirzepatide) injection prescribing information. DailyMed (FDA label). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0

Related comparisons

See the full drug-vs-drug verdict index or provider rankings.